#1 Clinical Trials Search in Europe

Melphalan Flufenamide

Melphalan Flufenamide, also known as Melflufen, is an investigational drug being studied in clinical trials for the treatment of multiple myeloma, particularly in patients with relapsed or refractory disease. This article explores the use of Melphalan Flufenamide in various clinical trials, its potential benefits, and what patients need to know about this promising new therapy.

Table of Contents

What is Melphalan Flufenamide (Melflufen)?

Melphalan flufenamide, also known as melflufen, is an investigational anti-cancer drug that belongs to a new class of compounds called peptide-drug conjugates (PDCs)[1]. It is being studied as a potential treatment for multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow[2].

How Does Melflufen Work?

Melflufen works in a unique way compared to other cancer treatments. Here’s how it functions:

  • It targets enzymes called aminopeptidases, which are often found in high levels in cancer cells[1].
  • Once inside the cancer cell, melflufen is rapidly broken down by these enzymes, releasing an anti-cancer substance called an alkylating agent[2].
  • This process allows melflufen to deliver a high concentration of the cancer-fighting agent directly into tumor cells[2].
  • The released alkylating agents then cause damage to the DNA of cancer cells, leading to their death[2].

This targeted approach may make melflufen more effective than traditional chemotherapy drugs while potentially reducing side effects on healthy cells[2].

What Conditions Does Melflufen Treat?

Melflufen is primarily being studied for the treatment of multiple myeloma, particularly in patients whose disease has returned or become resistant to other treatments. Specifically, it’s being investigated for:

  • Relapsed and/or refractory multiple myeloma: This refers to multiple myeloma that has returned after treatment or has not responded well to previous treatments[1][2].
  • Triple-class refractory multiple myeloma: This is a particularly challenging form of the disease that has become resistant to three main classes of myeloma drugs: proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies[1].
  • AL Amyloidosis: This is a rare disease related to multiple myeloma, where abnormal proteins build up in organs and tissues[3].

How is Melflufen Administered?

Melflufen is typically given as follows:

  • It is administered as an intravenous (IV) infusion, usually over 30 minutes[1][2].
  • The standard dose is often 40 mg, given once every 28 days (forming a treatment cycle)[1][2].
  • It is usually given in combination with dexamethasone, a steroid that helps enhance its effects[1][2].
  • Some studies are also looking at combining melflufen with other myeloma drugs like bortezomib or daratumumab[5][9].

Efficacy of Melflufen

Clinical trials have shown promising results for melflufen in treating multiple myeloma:

  • Overall Response Rate (ORR): In various studies, between 26% and 40% of patients with heavily pre-treated multiple myeloma showed a significant response to melflufen[2][6].
  • Progression-Free Survival (PFS): Some studies have reported a median PFS of 4-6 months, meaning half of the patients went at least this long without their disease worsening[6].
  • Duration of Response: For patients who responded to treatment, the benefits often lasted several months[6].

It’s important to note that these results are from patients with very advanced disease who had already tried multiple other treatments.

Side Effects and Safety

Like all cancer treatments, melflufen can cause side effects. The most common ones reported in clinical trials include:

  • Low blood cell counts: This can lead to increased risk of infections, fatigue, and easy bruising or bleeding[6].
  • Gastrointestinal issues: Such as nausea, diarrhea, or loss of appetite[6].
  • Fatigue: Feeling very tired is a common side effect[6].

Your healthcare team will monitor you closely for these and other potential side effects. They may adjust your dose or provide supportive treatments to help manage any issues that arise.

Ongoing Research

Several clinical trials are currently underway to further investigate melflufen:

  • Comparing melflufen to other treatments like pomalidomide in relapsed/refractory multiple myeloma[7].
  • Studying melflufen in combination with other myeloma drugs like daratumumab[9].
  • Investigating its use in patients with impaired kidney function, which is common in multiple myeloma[4].
  • Exploring its potential in treating AL amyloidosis[3].

These ongoing studies will help researchers better understand how to use melflufen most effectively and safely in different patient populations.

Aspect Details
Drug Name Melphalan Flufenamide (Melflufen)
Type of Drug Peptide-drug conjugate (PDC)
Mechanism of Action Targets aminopeptidases and rapidly releases alkylating agents into tumor cells
Primary Indication Relapsed or Refractory Multiple Myeloma
Administration Intravenous infusion, typically on Day 1 of each treatment cycle
Common Combination Often combined with dexamethasone
Key Outcomes Measured Overall Response Rate (ORR), Progression-Free Survival (PFS), Duration of Response (DOR)
Notable Side Effects Thrombocytopenia, neutropenia (full safety profile still under evaluation)
Clinical Trial Phases Phase 1, 2, and 3 trials conducted or ongoing
Patient Population Typically patients who have received at least 2-4 prior lines of therapy

FAQ

  • What is Melphalan Flufenamide? Melphalan Flufenamide, also known as Melflufen, is an investigational peptide-drug conjugate that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. It is being studied as a potential treatment for multiple myeloma, especially in patients whose disease has relapsed or become resistant to other therapies.
  • How is Melphalan Flufenamide administered? Melphalan Flufenamide is typically administered as an intravenous infusion, usually on day 1 of each treatment cycle. The treatment cycles can be 21 or 28 days long, depending on the specific clinical trial protocol.
  • What are the potential benefits of Melphalan Flufenamide? Clinical trials are investigating Melphalan Flufenamide's potential to improve outcomes for multiple myeloma patients, particularly those who have relapsed or become refractory to other treatments. Some studies have shown promising results in terms of overall response rates and progression-free survival.
  • Are there any side effects associated with Melphalan Flufenamide? As with any cancer treatment, Melphalan Flufenamide may cause side effects. Common side effects observed in clinical trials include hematological effects such as thrombocytopenia and neutropenia. The full safety profile is still being evaluated in ongoing clinical trials.
  • Who is eligible to participate in Melphalan Flufenamide clinical trials? Eligibility criteria vary between trials, but generally include patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy. Some trials focus on patients who are refractory to specific treatments like lenalidomide or who have impaired renal function. It's best to consult with your healthcare provider about specific trial eligibility.

Ongoing Clinical Trials on Melphalan Flufenamide

  • Study on the Effectiveness of Autologous Stem Cell Transplantation with Cytarabine in Patients with Aggressive Multiple Sclerosis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Melflufen and Dexamethasone for Elderly Patients with Relapsed Multiple Myeloma

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Italy

Glossary

  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell that produces antibodies to fight infections.
  • Relapsed Multiple Myeloma: When multiple myeloma returns after a period of remission or response to treatment.
  • Refractory Multiple Myeloma: When multiple myeloma does not respond to treatment or stops responding to treatment.
  • Peptide-drug conjugate (PDC): A type of drug that combines a peptide (a short chain of amino acids) with a therapeutic agent to target specific cells in the body.
  • Aminopeptidases: Enzymes that remove amino acids from the beginning of protein molecules, which are targeted by Melphalan Flufenamide.
  • Alkylating agents: A class of chemotherapy drugs that work by damaging the DNA of cancer cells, preventing them from dividing and growing.
  • Intravenous (IV) infusion: A method of administering medication directly into a vein using a needle or catheter.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Complete Response (CR): When all signs of cancer disappear in response to treatment.
  • Partial Response (PR): A decrease in the size of a tumor or in the extent of cancer in the body in response to treatment.
  • Dexamethasone: A corticosteroid medication often used in combination with other drugs to treat multiple myeloma.
  • Thrombocytopenia: A condition characterized by abnormally low levels of platelets in the blood, which can lead to easy bruising and bleeding.
  • Neutropenia: A condition characterized by an abnormally low count of neutrophils, a type of white blood cell important for fighting infections.

References

  1. https://clinicaltrials.gov/study/NCT04534322
  2. https://clinicaltrials.gov/study/NCT02963493
  3. https://clinicaltrials.gov/study/NCT04115956
  4. https://clinicaltrials.gov/study/NCT03639610
  5. https://clinicaltrials.gov/study/NCT03481556
  6. https://clinicaltrials.gov/study/NCT01897714
  7. https://clinicaltrials.gov/study/NCT03151811
  8. https://clinicaltrials.gov/study/NCT06682637
  9. https://clinicaltrials.gov/study/NCT04649060